[A25-24] Dostarlimab (endometrial cancer, pMMR) – Benefit assessment according to §35a Social Code Book V
Last updated 15.05.2025
Project no.:
A25-24
Commission:
Commission awarded on 13.02.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
First-line treatment of adult patients with primary advanced endometrial cancer or recurrent endometrial cancer with mismatch repair proficiency and who are candidates for systemic therapy
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-24
| Project no. | Title | Status |
|---|---|---|
| A23-143 | Dostarlimab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-84 | Dostarlimab (endometrial cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |